Last reviewed · How we verify
Nifedipine (Adalat, BAYA1040)
Nifedipine blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased cardiac contractility.
Nifedipine blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased cardiac contractility. Used for Hypertension, Angina pectoris, Coronary artery spasm (Prinzmetal's angina).
At a glance
| Generic name | Nifedipine (Adalat, BAYA1040) |
|---|---|
| Sponsor | Bayer |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of calcium ions through L-type calcium channels in the cell membrane. This reduces intracellular calcium concentration, leading to relaxation of vascular smooth muscle cells and resulting in peripheral vasodilation and reduced blood pressure. It also has mild negative inotropic effects on the heart.
Approved indications
- Hypertension
- Angina pectoris
- Coronary artery spasm (Prinzmetal's angina)
Common side effects
- Headache
- Flushing
- Dizziness
- Peripheral edema
- Palpitations
- Fatigue
- Gingival hyperplasia
Key clinical trials
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (PHASE3)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine (Adalat, BAYA1040) CI brief — competitive landscape report
- Nifedipine (Adalat, BAYA1040) updates RSS · CI watch RSS
- Bayer portfolio CI